Regeneron Pharmaceuticals has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of its Ebola treatment, Inmazeb, for U.S. preparedness.
The deal, valued at approximately $270 million, will see Regeneron deliver treatments through 2031, building on an original 2020 procurement contract, according to grafa.com.
Expanded Ebola Treatment Supply
The significant extension aims to bolster the United States’ readiness for potential Ebola outbreaks. The agreement ensures a continued supply of Inmazeb, Regeneron’s FDA-approved therapy for infections caused by Orthoebolavirus zairense.
Sources including StreetInsider reported the $270 million value of the extended supply deal.
Understanding Inmazeb
Inmazeb is a unique treatment comprising three monoclonal antibodies: atoltivimab, maftivimab, and odesivimab-ebgn. It is approved by the U.S. Food and Drug Administration (FDA) for treating Orthoebolavirus zairense infections in both adults and children, including newborns born to infected mothers.
Research into Bundibugyo Virus
In a separate but related development, Regeneron is also contributing to efforts against the Bundibugyo virus. The company is adding investigational maftivimab, one of the components of Inmazeb, to the PARTNERS clinical trial.
This trial, sponsored by the World Health Organization and internationally coordinated by the University of Oxford’s Pandemic Sciences Institute, is evaluating maftivimab’s potential against Bundibugyo virus disease amidst an ongoing outbreak in the Democratic Republic of the Congo. Currently, no treatments are specifically approved for Bundibugyo virus disease.
Laboratory and non-human primate studies have indicated activity against the Bundibugyo virus; however, these findings are presently available as a preprint awaiting peer review and have not yet established clinical efficacy in humans.
Frequently Asked Questions
- What is the value of Regeneron’s extended agreement?
The extended agreement with BARDA is valued at approximately $270 million. - What is Inmazeb?
Inmazeb is an FDA-approved Ebola treatment comprising three monoclonal antibodies—atoltivimab, maftivimab, and odesivimab-ebgn—used for infections caused by Orthoebolavirus zairense. - What is the PARTNERS clinical trial investigating?
The PARTNERS clinical trial is evaluating the potential of investigational maftivimab against Bundibugyo virus disease during an ongoing outbreak in the Democratic Republic of the Congo.
